IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced today the appointment of Julie Hambleton, M.D., as senior vice president and chief medical officer, head of development. Dr. Hambleton brings more than 20 years of experience in clinical drug development, ranging from pre-clinical studies through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filing of investigational new drug applications (INDs), biologics license applications (BLAs), and special protocol assessments (SPAs).
“Dr. Hambleton is an accomplished industry executive and a leading oncology drug developer, and we welcome her to the leadership team at IDEAYA,” said Yujiro S. Hata, chief executive officer of IDEAYA. “Dr. Hambleton’s unique clinical background in both immuno-oncology and synthetic lethality will strengthen our organization’s capabilities as we advance multiple first-in-class programs into the clinic, leveraging our clinical strategy in patient selection and combinations.”
Julie Hambleton, M.D.
“Over the past two decades, I have been involved in the development of numerous targeted and biomarker enabled therapies, including Avastin® and Rubraca®, and first-in-class immuno-oncology agents that have been developed in combination with checkpoint inhibitors,” said Dr. Hambleton. “IDEAYA’s diverse pipeline of biomarker enabled synthetic lethality programs and immunotherapies targeting immuno-metabolism and innate immunity have the potential to transform oncology care and deliver on our mission to bring innovative personalized therapies to cancer patients.”
Dr. Hambleton was previously vice president, head of US medical at Bristol-Myers Squibb, overseeing medical & health economic and outcomes research activities in support of the oncology, immuno-oncology, specialty and cardiovascular marketed portfolios. From 2012 to 2016, she was executive vice president and chief medical officer at Five Prime Therapeutics, where she led clinical, clinical operations, regulatory, preclinical and translational and process development and was a member of the executive committee. From 2010 to 2012, Dr. Hambleton was vice president, clinical development, at Clovis Oncology, where she oversaw clinical development programs and managed clinical and pharmacokinetic functions, including the development of Rubraca, a PARP inhibitor, developed with a diagnostic for BRCA and HRD. From 2003 to 2010, she was at Genentech, most recently as group medical director, global clinical development, leading a cross-functional group conducting multiple Phase 2 and 3 trials of Avastin.
Prior to joining industry, Dr. Hambleton served from 1993 to 2003 in academic positions in the division of hematology-oncology at the University of California, San Francisco (UCSF), most recently as associate professor of clinical medicine. She completed post-graduate training at UCSF, where she served as medical resident, chief medical resident and fellow in the division of hematology-oncology. She received a B.S. from Duke University in nursing, an M.D. from Case Western Reserve University School of Medicine, and was board-certified in hematology and internal medicine.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, immunology, and small molecule drug discovery.
SVP, Head of Corporate Development